Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Background:

• Lipoprotein(a) (Lp(a)) is an independent risk factor for recurrent atherosclerotic heart disease (AHD) in both men and postmenopausal women.
• Elevated Lp(a) levels are prevalent in specific populations, including Africans, African Americans, and Asian populations, and are not routinely included in standard lipid profiles.
• Separate testing for Lp(a) is necessary for accurate cardiovascular risk assessment.

Observation:

• Screening for Lp(a) is recommended for individuals with a personal or family history of premature AHD or hyperlipidemia.
• Consider Lp(a) testing in patients with established AHD and normal lipid profiles, refractory hyperlipidemia, or recurrent arterial stenosis.
• Lp(a) levels are not affected by standard low-density lipoprotein (LDL) lowering therapies like statins.

Findings:

• Extended-release niacin (3-4 g daily) is effective in reducing Lp(a) and AHD mortality but may have side effects.
• Estrogen replacement therapy in postmenopausal women can impact Lp(a), though progesterone may diminish its effectiveness.
• Aspirin and antibiotics may be beneficial for high C-reactive protein levels, while folic acid can lower homocysteine.

Implications:

• Early identification of elevated Lp(a) enables targeted interventions to mitigate cardiovascular risk.
• A multi-faceted approach combining specific Lp(a) treatments with general cardiovascular disease prevention strategies is essential.
• Further research into effective and well-tolerated treatments for managing high Lp(a) is warranted.